DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Phase 1

Terminated

Conditions: Cancer
Solid Tumor
Advanced Solid Tumor

Interventions: Drug: BGT226

First Posted Date: 2008-08-27

Last Posted Date: 2018-09-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT00742105

Locations: 🇯🇵
Novartis Investigative Site, Kobe-shi, Hyogo, Japan

Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Classical Hodgkin's Lymphoma

Interventions: Drug: Panobinostat

First Posted Date: 2008-08-27

Last Posted Date: 2021-07-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 129

Registration Number: NCT00742027

Locations: 🇺🇸
University of Pennsylvania Medical Center Dept of UPenn Med Ctr (3), Philadelphia, Pennsylvania, United States
🇺🇸
West Virginia University/ Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
🇺🇸
Rush University Medical Center Divisionof Hem/Onc Research(2), Chicago, Illinois, United States

and more 11 locations

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma Bone Disease

Interventions: Drug: BHQ880
Drug: Zoledronic acid

First Posted Date: 2008-08-26

Last Posted Date: 2013-02-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT00741377

Locations: 🇺🇸
Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas, United States
🇺🇸
MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (11), Houston, Texas, United States
🇺🇸
Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale, Arizona, United States

and more 3 locations

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2008-08-22

Last Posted Date: 2016-10-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 332

Registration Number: NCT00739596

Locations: 🇺🇸
Sites in USA, East Hanover, New Jersey, United States

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Aliskiren 150 mg tablet
Drug: Aliskiren 300 mg tablet
Drug: Amlodipine 5 mg capsule
Drug: Amlodipine 10 mg capsule
Drug: Aliskiren/amlodipine 150/10 mg tablet
Drug: Aliskiren/amlodipine 300/5 mg tablet
Drug: Aliskiren/amlodipine 150/5 mg tablet
Drug: Aliskiren/amlodipine 300/10 mg tablet

First Posted Date: 2008-08-22

Last Posted Date: 2011-06-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2694

Registration Number: NCT00739973

Locations: 🇦🇺
Invesigative Site, Canberra, Australia
🇨🇳
Investigative Site, Taipei, Taiwan

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Phase 4

Completed

Conditions: Paget's Disease of the Bone

Interventions: Drug: Zoledronic Acid

First Posted Date: 2008-08-22

Last Posted Date: 2021-05-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT00740129

Locations: 🇬🇧
Novartis Investigative site, Oxford, United Kingdom

Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer
Advanced Solid Tumor

Interventions: Drug: LBH589

First Posted Date: 2008-08-21

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT00739414

Locations: 🇯🇵
Novartis Investigational Site, Hyogo prefecture, Japan

A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.

Phase 4

Completed

Conditions: Bone Loss

Interventions: Drug: Pamidronate

First Posted Date: 2008-08-20

Last Posted Date: 2010-05-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 126

Registration Number: NCT00738257

Locations: 🇬🇧
Novartis Investigative Site, Frimley, United Kingdom

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: ASA404
Drug: docetaxel

First Posted Date: 2008-08-20

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 900

Registration Number: NCT00738387

Locations: 🇺🇸
UT Southwester Med Ctr at Dallas, Dallas, Texas, United States
🇺🇸
Texas Cancer Center - Denton, Denton, Texas, United States
🇺🇸
Longview Cancer Center, Longview, Texas, United States

and more 87 locations

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Phase 3

Terminated

Conditions: Primary Progressive Multiple Sclerosis

Interventions: Drug: Placebo
Drug: FTY720

First Posted Date: 2008-08-11

Last Posted Date: 2017-06-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 970

Registration Number: NCT00731692

Locations: 🇬🇧
Novartis Investigative Site, Norwich, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy